Pulmonary and Critical Care Divisions, Departments of Medicine, Intermountain Healthcare Urban Central, Murray, Utah 84157-7000, USA.
Curr Opin Crit Care. 2013 Feb;19(1):38-43. doi: 10.1097/MCC.0b013e32835c2ac8.
To evaluate the last 2 years' publications for evidence supporting use of extracorporeal membrane oxygenation (ECMO) for critically ill adults with acute respiratory distress syndrome (ARDS).
First, there are no new prospective studies comparing ECMO and other therapy in adults with ARDS. Second, the number of review articles and case descriptions published in the last 2 years suggests increased interest in ECMO. Third, recently published retrospective cohort studies analyzing patients from the H1N1 epidemic report conflicting conclusions.
Intensivists may have increased their utilization of ECMO. Credible evidence for mortality benefit of ECMO is lacking. A prospective randomized controlled trial designed to evaluate the efficacy of ECMO for ARDS is overdue.
评估过去 2 年的文献，以获取支持体外膜氧合（ECMO）用于治疗急性呼吸窘迫综合征（ARDS）危重症成人的证据。
首先，没有新的前瞻性研究比较 ECMO 和其他疗法在成人 ARDS 中的应用。其次，过去 2 年发表的综述文章和病例描述数量表明，人们对 ECMO 的兴趣有所增加。第三，最近发表的回顾性队列研究分析了 H1N1 流行期间的患者，得出了相互矛盾的结论。
重症监护医生可能增加了 ECMO 的使用。缺乏 ECMO 对死亡率有益的确切证据。设计用于评估 ECMO 治疗 ARDS 疗效的前瞻性随机对照试验已经滞后。
Zotero 插件